Neovascular Glaucoma
Neovascular Glaucoma
复制标题
DOI：
10.1159/000431196
复制
发表时间：
2016-01-01
期刊：
影响因子：
--
通讯作者：
Gulati, Vikas
中科院分区：
文献类型：
--
作者：
Havens, Shane J.;Gulati, Vikas
新生血管性青光眼(NVG)是一种继发性眼部病变，由多种眼部和全身疾病引起，95%以上的病例以视网膜缺血为中介。NVG是由于局部血管生成刺激导致的纤维血管膜在小梁网上生长，阻碍房水流出所致。这导致了最初的继发性开角型青光眼阶段，这可能适用于降低眼压的药物和潜在的缺血过程的调节，通常结合全视网膜光凝和辅助使用血管内皮生长因子抑制剂。在新生血管的晚期，结缔组织肌成纤维细胞与新血管的生长收缩相关，导致前房角的渐进性粘连闭合。一旦继发房角关闭，眼压升高往往对外用和口服降眼压药物无效，通常需要青光眼手术治疗。(C)2016年S.Karger AG，巴塞尔
Neovascular glaucoma (NVG) is a secondary ocular pathological condition resulting from a myriad of ocular and systemic conditions with retinal ischemia as a mediator in over 95% of cases. NVG is caused by the growth of a fibrovascular membrane secondary to a local angiogenic stimulus over the trabecular meshwork obstructing aqueous outflow. This results in an initial secondary open-angle glaucoma stage that may be amenable to intraocular pressure (IOP)-lowering medications and modulation of the underlying ischemic process, often in combination with panretinal photocoagulation and adjunctive use of vascular endothelial growth factor inhibitors. In the more advanced stages of neovascularization, connective tissue myofibroblasts associated with new vessel growth contract causing progressive synechial closure of the anterior-chamber angle. Elevation of IOP, once significant secondary angle closure is established, tends to be refractory to topical and oral IOP-lowering medications and often requires glaucoma surgical interventions. (C) 2016 S. Karger AG, Basel